Marker Therapeutics, Inc. (MRKR), Thursday announced an update from its APOLLO study investigating MT-601 in patients with relapsed lymphoma.
The company found that 78 percent of patients achieved objective response rates, with 44.4 percent demonstrating complete response. Moreover, MT-601 was well tolerated with no observation of immune-effector cell associated neurotoxicity syndrome.
Concurrently with the update, Marker also announced the decision to sell around 5.03 million shares at $3.20 a share to raise $16.1 million in private placement.
The company intends to use the proceeds to fund Phase 1 APOLLO study.
Currently, Marker's stock is trading at $3.96, down 1.63 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.